OBJECTIVES: Dyslipidemia is the most common reason of atherosclerosis which is associated with the high risk of myocardial infarction, cerebrovascular diseases and other cardiovascular complications. Cholesterol lowering therapy has been shown to reduce cardiovascular mortality and morbidity. National and international guidelines have defined LDL-cholesterol treatment initiation levels and aims for patients with different levels of coronary heart disease risk according to the number of coronary heart disease risk factors associated to dyslipidemia. It is crucial for health care system to analyze utilisation and costs of hypolipdemics. Adherence to the short and long term treatment guidelines could lead to financial saving in health care systems. The aim of the study was to collect comparable and reliable data on the lipid lowering therapy in Slovak republic during 1998-2005. METHODS: Data used for analyses were obtained from the Slovak Institute for Drug Control. Wholesalers are legally obliged provide the drug consumption information to the institute. RESULTS: The obtained data showed large increases hypolipidemics consumption from 1998 to 2005 (from 7.34 DID (DDD per 1000 inhabitants per day) in 1998 to 39.12 DID in 2005). Consumption of statins was significant (from 1.96 DID in 1998 to 3.16 DID in 2005). Consumption of fibrates increased moderate (from 5.12 DID in 1998 to 8.72 DID in 2005). Lipid lowers generics coming into the pharmaceutical market led to the price cut-downing (from € 0.95/DDD to € 0.64 per DDD). CONCLUSION: Lipid lowering generics drug coming into the Slovak pharmaceutical market led to increased of lipid lowers consumption and to price reduction of lipid lowers. Financial expenditures for health insurance companiesx funds remained under control and more patients could be treated for high cholesterol levels and high risk of cardiovascular diseases in Slovak republic during 1998-2005.